Previous 10 | Next 10 |
2023-05-15 18:15:06 ET Hedge fund manager David Einhorn's Greenlight Capital picked up new stakes in Black Knight ( BKI ), First Citizens BancShares ( FCNCA ) and New York Community Bancorp ( NYSE: NYCB ) during Q1, its latest 13F filing showed. The company e...
2023-05-06 01:59:04 ET Summary Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T therapies with encouraging initial safety and efficacy...
2023-05-05 12:47:05 ET Galapagos NV (GLPG) Q1 2023 Earnings Conference Call May 05, 2023, 08:00 ET Company Participants Sofie Van Gijsel - Head, IR Paulus Stoffels - CEO, Chairman, Interim Head, R&D Bart Filius - President, COO & CFO Michele Manto - C...
2023-05-04 16:04:37 ET Galapagos press release ( NASDAQ: GLPG ): Q1 GAAP EPS of €0.40. Revenue of €178.9M (+31.3% Y/Y). Current financial investments and cash and cash equivalents totaled €3,990.1 million on 31 March 2023, as compared to ...
P rogress with i mmunology and oncology pipeline : First patients dosed in pivotal Phase 3 OLINGUITO study with filgotinib in axial spondyloarthritis ( AxSpA ) Clinical sites opened to start patient recruitment in Pha...
2023-05-03 03:11:20 ET Galapagos ( NASDAQ: GLPG ) notifies the departure of Bart Filius, President, Chief Operating Officer and Chief Financial Officer. Bart Filius will leave the company as per 30 June 2023. A search for successor is underway. ...
Mechelen, Belgium; 2 May 2023, 22:01 CET ; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today announced the departure of Bart Filius , President, Chief Operating Officer and Chief Financial Officer . ...
OLINGUITO Phase 3 program in adults with axial spondyloarthritis (AxSpA) to include two parallel studies to investigate the efficacy and safety of filgotinib in patients with active radiographic AxSpA (r-AxSpA) and non-radiographic AxSpA (nr-AxSpA) Results from Phase 2 TORTUGA study showed th...
Mechelen, Belgium; 2 5 April 2023 , 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announces the approval of all resolutions proposed at its annual shareholders’ meeting (AGM) held today at 14.00 CET. The AGM appr...
2023-03-30 18:39:41 ET Belgian biotech Galapagos NV ( NASDAQ: GLPG ) on Thursday said it would transfer its drug discovery and research activities in Romainville, France to contract research organization NovAliX. NovAliX will assume GLPG's research capabilities while...
News, Short Squeeze, Breakout and More Instantly...
2024-07-11 21:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next-generation MAGE-A4 TCR T-cell therapy) produced on Galapagos' decentralized manufacturing platform in patients with head & neck cancer Uza-cel has shown encouraging resul...